Sign In
Buy ORGO
$2.33
+0.0900 (+4.02%)
At Close: Jun 03, 2026
Organogenesis Expands Manufacturing Capacity to Support Future Growth
04:05pm, Friday, 22'nd Nov 2024
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Commends Final LCDs
09:25am, Friday, 15'th Nov 2024
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Loc
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript
11:02pm, Tuesday, 12'th Nov 2024
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francis
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
04:01pm, Tuesday, 12'th Nov 2024
Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic grow
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
05:05pm, Monday, 11'th Nov 2024
CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
07:30am, Wednesday, 16'th Oct 2024
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock
09:51am, Tuesday, 15'th Oct 2024
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that p
CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
04:05pm, Wednesday, 04'th Sep 2024
CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript
11:08pm, Thursday, 08'th Aug 2024
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco
Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
07:36pm, Thursday, 08'th Aug 2024
Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago.
Organogenesis Shares ReNu® Program Update
04:04pm, Thursday, 08'th Aug 2024
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
04:05pm, Monday, 15'th Jul 2024
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
04:05pm, Thursday, 06'th Jun 2024
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript
09:01pm, Thursday, 09'th May 2024
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - C
